Duchenne News Tags: Entrada Therapeutics

November 27, 2023
Entrada announces the completion of dosing for the first and second cohorts of its Phase 1 clinical trial, ENTR-601-44-101.
November 7, 2023
Entrada reports third quarter 2023 financial results and more business updates.
September 21, 2023
Entrada announces the first participant has been dosed in its Phase 1 clinical trial evaluating ENTR-601-44 for the potential treatment of individuals with Duchenne muscular dystrophy who are exon 44...
August 7, 2023
Entrada announces authorization for its CTIMP for a Phase 1 clinical trial in healthy volunteers for ENTR-601-44
January 10, 2023
Entrada announces the selection of a second clinical candidate within its Duchenne franchise, ENTR-601-45
December 21, 2022
Entrada announces clinical hold notice from U.S. FDA regarding IND for ENTR-601-44

Accessible Vehicle Fund Applications Open